Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2016

Fair Value Disclosures [Abstract]

Summary of Asset and Liability Fair Values

The table below summarizes certain asset and liability fair values that are included within our accompanying Consolidated Balance Sheets, and their designations among the three fair value measurement categories:

	December 31, 2016 Fair Value Measurements
	Level 1		Level 2		Level 3		Total
Assets:
Bank certificates of deposits	$	—	$	5,991	$	—	$	5,991
Money market funds	—		128,563		—		128,563
Equity securities (Note 11)	11,533		—		—		11,533
Mutual funds	—		56		—		56
Deferred compensation investments (life insurance cash surrender value)	—		11,863		—		11,863		*
	$	11,533	$	146,473	$	—	$	158,006
Liabilities:
Deferred executive compensation liability (Note 17(f))	—		8,352		—		8,352		*
Drug development liability (Note 16)	—		—		13,130		13,130
Ligand Contingent Consideration (Note 10 (b))	—		—		—		—
Talon CVR (Note 10 (a))	—		—		1,253		1,253
Corixa Liability	—		—		62		62
	$	—	$	8,352	$	14,445	$	22,797

	December 31, 2015 Fair Value Measurements
	Level 1		Level 2		Level 3		Total
Assets:
Bank certificates of deposits	$	—	$	245	$	—	$	245
Money market funds	—		80,116		—		80,116
Equity securities	5,189		—		—		5,189
Deferred compensation investments (life insurance cash surrender value)	—		9,181		—		9,181		*
	$	5,189	$	89,542	$	—	$	94,731
Liabilities:
Deferred executive compensation liability	—		6,458		—		6,458		*
Drug development liability	—		—		14,686		14,686
Ligand Contingent Consideration	—		—		5,227		5,227
Talon CVR	—		—		1,377		1,377
Corixa Liability	—		—		62		62
	$	—	$	6,458	$	21,352	$	27,810

* The reported value of "deferred compensation investments" is based on the cash surrender value of the life insurance policies, while the value of the "deferred executive compensation liability" is based on the market value of the underlying investment holdings.

Activity of Level 3 Inputs Measured on Recurring Basis

The following presents a roll forward of our liabilities for which we utilize Level 3 inputs in determining period-end value. These liabilities are included on our Consolidated Balance Sheets within “acquisition related contingent obligations” and “drug development liability”. The basis of the various Level 2 and Level 3 valuation inputs are discussed in Note 2(xiii).

Our carrying amounts of financial instruments such as cash equivalents, accounts receivable, prepaid expenses, accounts payable, and accrued liabilities, excluding acquisition-related contingent consideration obligations, approximate their related fair values due to their short-term nature.

	Fair Value Measurements of Unobservable Inputs (Level 3)
Balance at December 31, 2014	$	23,127
Deferred drug development costs	(1,099		)
Ligand Contingent Consideration fair value adjustment	326
Talon CVR fair value adjustment	(1,002		)
Balance at December 31, 2015	$	21,352
Settlement of Ligand Contingent Consideration liability (Note 10(b))	(6,000		)
Deferred drug development costs (Note 16)	(1,556		)
Ligand Contingent Consideration fair value adjustment prior to settlement (Note 10(b))	773
Talon CVR fair value adjustment (Note 10(a))	(124		)
Balance at December 31, 2016	$	14,445		*

* This amount is comprised of the current and non-current portions of "drug development liability" and of "acquisition-related contingent obligations" on our accompanying Consolidated Balance Sheets.